Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and Caris Life Sciences, Inc. (CAI)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Xenon (XENE – Research Report) and Caris Life Sciences, Inc. (CAI – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Xenon (XENE)
In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Xenon, with a price target of $53.00. The company’s shares closed last Thursday at $44.92, close to its 52-week high of $46.00.
According to TipRanks.com, Tsao is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Xenon with a $56.18 average price target, representing a 26.0% upside. In a report issued on February 23, Wolfe Research also initiated coverage with a Buy rating on the stock with a $60.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Caris Life Sciences, Inc. (CAI)
TD Cowen analyst Daniel Brennan maintained a Buy rating on Caris Life Sciences, Inc. today and set a price target of $35.00. The company’s shares closed last Thursday at $19.24, close to its 52-week low of $17.15.
According to TipRanks.com, Brennan is a 5-star analyst with an average return of
Caris Life Sciences, Inc. has an analyst consensus of Strong Buy, with a price target consensus of $40.67, which is an 119.8% upside from current levels. In a report issued on February 17, Robert W. Baird also initiated coverage with a Buy rating on the stock with a $26.00 price target.
